Properdin Is a Modulator of Tumour Immunity in a Syngeneic Mouse Melanoma Model
Abstract
:1. Introduction
2. Materials and Methods
2.1. Mice
2.2. Cells
2.3. Determination of Tumour Mass, Bioimaging
2.4. Proteome Array Analysis
2.5. ELISA
2.6. Flow Cytometry
2.7. Statistical Analysis
3. Results
3.1. Properdin-Deficient and Wildtype Mice Have Comparable Tumour Load
3.2. Inflammatory Marker Expression in B16 Tumours is Altered in Properdin-Deficient Mice
3.3. Tumour-Bearing Properdin-Deficient Mice Have Dysregulated Systemic and Tumour Associated Responses
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Day, C.P.; Merlino, G.; Van Dyke, T. Preclinical mouse cancer models: A maze of opportunities and challenges. Cell 2015, 163, 39–53. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dunn, G.P.; Old, L.J.; Schreiber, R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 2004, 22, 329–360. [Google Scholar] [CrossRef] [PubMed]
- Yu, J.W.; Bhattacharya, S.; Yanamandra, N.; Kilian, D.; Shi, H.; Yadavilli, S.; Katlinskaya, Y.; Kaczynski, H.; Conner, M.; Benson, W.; et al. Tumor-immune profiling of murine syngeneic tumor models as a framework to guide mechanistic studies and predict therapy response in distinct tumor microenvironments. PLoS ONE. 2018, 13, e0206223. [Google Scholar] [CrossRef] [PubMed]
- Lechner, M.G.; Karimi, S.S.; Barry-Holson, K.; Angell, T.E.; Murphy, K.A.; Church, C.H.; Ohlfest, J.R.; Hu, P.; Epstein, A.L. Immunogenicity of murine solid tumor models as a defining feature of in vivo behavior and response to immunotherapy. J. Immunother. 2013, 36, 477–489. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Salehen, N.; Stover, C. The role of complement in the success of vaccination with conjugated vs. unconjugated polysaccharide antigen. Vaccine 2008, 26, 451–459. [Google Scholar] [CrossRef] [Green Version]
- Bronte, V.; Pittet, M.J. The spleen in local and systemic regulation of immunity. Immunity 2013, 39, 806–818. [Google Scholar] [CrossRef] [Green Version]
- Cortez-Retamozo, V.; Etzrodt, M.; Newton, A.; Rauch, P.J.; Chudnovskiy, A.; Berger, C.; Ryan, R.J.; Iwamoto, Y.; Marinelli, B.; Gorbatov, R.; et al. Origins of tumor-associated macrophages and neutrophils. Proc. Natl. Acad. Sci. USA 2012, 109, 2491–2496. [Google Scholar] [CrossRef] [Green Version]
- Afshar-Kharghan, V. The role of the complement system in cancer. J. Clin Investig. 2017, 127, 780–789. [Google Scholar] [CrossRef] [Green Version]
- Markiewski, M.; DeAngelis, R.; Benencia, F.; Ricklin-Lichtsteiner, S.; Koutoulaki, A.; Gerard, C.; Coukos, G.; Lambris, J. Modulation of the antitumor immune response by complement. Nat. Immunol. 2008, 9, 1225–1235. [Google Scholar] [CrossRef] [Green Version]
- Wang, Y.; Sun, S.N.; Liu, Q.; Yu, Y.Y.; Guo, J.; Wang, K.; Xing, B.C.; Zheng, Q.F.; Campa, M.J.; Patz, E.F., Jr.; et al. Autocrine Complement Inhibits IL10-Dependent T-cell-Mediated Antitumor Immunity to Promote Tumor Progression. Cancer Discov. 2016, 6, 1022–1035. [Google Scholar] [CrossRef] [Green Version]
- Nabizadeh, J.A.; Manthey, H.D.; Steyn, F.J.; Chen, W.; Widiapradja, A.; Md Akhir, F.N.; Boyle, G.M.; Taylor, S.M.; Woodruff, T.M.; Rolfe, B.E. The Complement C3a Receptor Contributes to Melanoma Tumorigenesis by Inhibiting Neutrophil and CD4+ T Cell Responses. J. Immunol. 2016, 196, 4783–4792. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Bulla, R.; Tripodo, C.; Rami, D.; Ling, G.S.; Agostinis, C.; Guarnotta, C.; Zorzet, S.; Durigutto, P.; Botto, M.; Tedesco, F. C1q acts in the tumour microenvironment as a cancer-promoting factor independently of complement activation. Nat. Commun. 2016, 7, 10346. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Al-Rayahi, I.A.; Browning, M.; Stover, C. Tumour cell conditioned medium reveals greater M2 skewing of macrophages in the absence of properdin: Properdin shapes macrophage activity in tumours. Immun. Inflamm. Dis. 2017, 5, 68–77. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stover, C.M.; Luckett, J.C.; Echtenacher, B.; Dupont, A.; Figgitt, S.E.; Brown, J.; Maennel, D.N.; Schwaeble, W.J. Properdin plays a protective role in polymicrobial septic peritonitis. J. Immunol. 2008, 180, 3313–3318. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stover, C. Dual role of complement in tumour growth and metastasis. Int. J. Mol. Med. 2010, 25, 307–313. [Google Scholar] [CrossRef]
- Varela, J.; Imai, M.; Atkinson, C.; Ohta, R.; Rapisardo, M.; Tomlinson, S. Modulation of protective T cell immunity by complement inhibitor expression on tumor cells. Cancer Res. 2008, 68, 6734–6742. [Google Scholar] [CrossRef] [Green Version]
- Corrales, L.; Ajona, D.; Rafail, S.; Lasarte, J.J.; Riezu-Boj, J.I.; Lambris, J.D.; Rouzaut, A.; Pajares, M.J.; Montuenga, L.M.; Pio, R. Anaphylatoxin C5a creates a favourable microenvironment for lung cancer progression. J. Immunol. 2012, 189, 4674–4683. [Google Scholar] [CrossRef]
- Izumi, S.; Hirai, K.; Miyamasu, M.; Takahashi, Y.; Misaki, Y.; Takaishi, T.; Morita, Y.; Matsushima, K.; Ida, N.; Nakamura, H.; et al. Expression and regulation of monocyte chemoattractant protein-1 by human eosinophils. Eur. J. Immunol. 1997, 27, 816–824. [Google Scholar] [CrossRef]
- Piao, C.; Cai, L.; Qiu, S.; Jia, L.; Song, W.; Du, J. Complement 5a Enhances Hepatic Metastases of Colon Cancer via Monocyte Chemoattractant Protein-1-mediated Inflammatory Cell Infiltration. J. Biol. Chem. 2015, 290, 10667–10676. [Google Scholar] [CrossRef] [Green Version]
- Conti, I.; Rollins, B.J. CCL2 (monocyte chemoattractant protein-1) and cancer. Semin. Cancer Biol. 2004, 14, 149–154. [Google Scholar] [CrossRef]
- Liu, J.; Jha, P.; Lyzogubov, V.V.; Tytarenko, R.G.; Bora, N.S.; Bora, P.S. Relationship between complement membrane attack complex, chemokine (C-C motif) ligand 2 (CCL2) and vascular endothelial growth factor in mouse model of laser-induced choroidal neovascularization. J. Biol. Chem. 2011, 286, 20991–21001. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Li, M.; Knight, D.A.; A Snyder, L.; Smyth, M.J.; Stewart, T.J. A role for CCL2 in both tumor progression and immunosurveillance. Oncoimmunology 2013, 2, e25474. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Sunderkötter, C.; Steinbrink, K.; Goebeler, M.; Bhardwaj, R.; Sorg, C. Macrophages and angiogenesis. J. Leukoc. Biol. 1994, 55, 410–422. [Google Scholar] [CrossRef] [PubMed]
- Sun, W.; Wei, F.Q.; Li, W.J.; Wei, J.W.; Zhong, H.; Wen, Y.H.; Lei, W.B.; Chen, L.; Li, H.; Lin, H.Q.; et al. A positive-feedback loop between tumour infiltrating activated Treg cells and type 2-skewed macrophages is essential for progression of laryngeal squamous cell carcinoma. Br. J. Cancer 2017, 117, 1631–1643. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mosely, S.I.; Prime, J.E.; Sainson, R.C.; Koopmann, J.O.; Wang, D.Y.; Greenawalt, D.M.; Ahdesmaki, M.J.; Leyland, R.; Mullins, S.; Pacelli, L.; et al. Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. Cancer Immunol. Res. 2017, 5, 29–41. [Google Scholar] [CrossRef] [Green Version]
- Ricklin, D.; Hajishengallis, G.; Yang, K.; Lambris, J.D. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 2010, 11, 785–797. [Google Scholar] [CrossRef] [Green Version]
- Lubbers, R.; van Essen, M.F.; van Kooten, C.; Trouw, L.A. Production of complement components by cells of the immune system. Clin. Exp. Immunol. 2017, 188, 183–194. [Google Scholar] [CrossRef] [Green Version]
- Reis, E.S.; Mastellos, D.C.; Ricklin, D.; Mantovani, A.; Lambris, J.D. Complement in cancer: Untangling an intricate relationship. Nat. Rev. Immunol. 2018, 18, 5–18. [Google Scholar] [CrossRef]
- Serafini, P.; Mgebroff, S.; Noonan, K.; Borrello, I. Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res. 2008, 68, 5439–5449. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, Y.; Lai, B.S.; Juhas, M. Recent Advances in Aptamer Discovery and Applications. Molecules 2019, 24, 941. [Google Scholar] [CrossRef] [Green Version]
PropWT (n = 3) | PropKO (n = 3) | p-Value | |
---|---|---|---|
TIMP1 | 45.72 ± 4.19 | 10.41 ± 0.91 | <0.002 |
IL-13 | 5.24 ± 1.36 | 0.88 ± 0.35 | <0.05 |
CCL2 | 97.49 ± 1.11 | 1.37 ± 0.17 | <0.0001 |
CCL3 | 46.31 ± 3.01 | 0.93 ± 0.41 | <0.0002 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Al-Rayahi, I.A.M.; Machado, L.R.; Stover, C.M. Properdin Is a Modulator of Tumour Immunity in a Syngeneic Mouse Melanoma Model. Medicina 2021, 57, 85. https://doi.org/10.3390/medicina57020085
Al-Rayahi IAM, Machado LR, Stover CM. Properdin Is a Modulator of Tumour Immunity in a Syngeneic Mouse Melanoma Model. Medicina. 2021; 57(2):85. https://doi.org/10.3390/medicina57020085
Chicago/Turabian StyleAl-Rayahi, Izzat A. M., Lee R. Machado, and Cordula M. Stover. 2021. "Properdin Is a Modulator of Tumour Immunity in a Syngeneic Mouse Melanoma Model" Medicina 57, no. 2: 85. https://doi.org/10.3390/medicina57020085